Dabigatran etexilate in patients with nonvalvular atrial fibrillation: benefits of application in certain clinical situations
https://doi.org/10.15829/1560-4071-2019-11-133-141
Abstract
The review discusses the problem of patient-oriented choice of anticoagulants for nonvalvular atrial fibrillation (AF). The efficacy and safety profile of dabigatran etexilate and a group of patients with advantage of dabigatran application: patients with a high risk or history of ischemic stroke, patients who are indicated for combination antithrombotic therapy, and patients with a high risk of emergency surgical interventions and procedures, as well as with a high risk of bleeding, etc. The place of idarucizumab, a direct dabigatran etexilate antagonist, is shown.
Supporting agencies: Boehringer Ingelheim
About the Authors
E. I. Baranova
Pavlov First Saint-Petersburg State Medical University; Almazov National Medical Research Center
Russian Federation
Russian Federation
St. Petersburg.
Zhanna Kobalava
The Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
Zhanna D. Kobalava - chief of internal medicine chair with course of cardiology and functional diagnosis, chief of cardiology and clinical pharmacology chair of faculty of enchansement qualification of physicians.
Moscow.
References
1. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation development in collaboration with EACTS. The Task Force for the management of atrial fibrillation of the European Society of cardiology (ESC). European Heart Journal. 2016;37:2893-962. doi:10.1093/eurheartj/ehw210.
2. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation. Circulation. 2019;139:e000-e000. doi:10.1161/CIR.0000000000000665.
3. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal. 2018;39(16):1330-93. doi:10.1093/eurheartj/ehy136.
4. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. doi:10.1056/NEJMoa0905561.
5. Diener HC, Connolly SJ, Ezekowitz MD, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010;9(12):1157-63. doi:10.1016/S1474-4422(10)70274-X.
6. Lip GYH, Lane DA. Matching the NOAC to the patient: remember the modifiable bleeding risk factors. JACC. 2015;66,21:2282-84. doi:10.1016/j.jacc.2015.07.086.
7. ldgren J, Alings M, Darius H, et al. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med. 2011;155(10):660-7. doi:10.7326/0003-4819-155-10-201111150-00004.
8. Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):1121-201. doi:10.1016/j.chest.2018.07.040.
9. Berrouschot J, Stoll A, Hogh T, Eschenfelder CC. Intravenous thrombolysis with recombinant tissue-type plasminogen activator in a stroke patient receiving dabigatran anticoagulant after antagonization with idarucizumab. Stroke. 2016;47:1936-8. doi:10.1161/STROKEAHA.116.013550.
10. Mutzenbach JS, Pikija S, Otto F, et al. Intravenous thrombolysis in acute ischemic stroke after reversal with idarucizumab: a case report. Ann Clin Transl Neurol. 2016;3:889-92. doi:10.1002/acn3.346.
11. Kermer P, Eschenfelder CC, Diener HC, Grond M. Idarucizumab in patients treated with dabigatran suffering cerebral ischemia or intracranial hemorrhage: a retrospective case series from Germany. Home Stroke. 2019;50(suppl.1): abstr.84. doi:10.1161/str.50.suppl_1.84.
12. Instructions for medical use of the drug Praxbind, RU № LP-005017. (In Russ.)
13. Instructions for use of the drug for medical use Pradaxa. RU: 75/110 mg LSR-007065/09; 150 mg-LP-000872. (In Russ.)
14. Shamalov NA, Khasanova DR, Stakhovskaya LV, et al. Reperfusion therapy for ischemic stroke. Clinical protocol. M., 2019. 80 p. (In Russ.)
15. Pollack CV Jr, Relly PA, van Ryan J, et al. Idarucizumab for dabigatran reversal — full cohort analysis. N Engl J Med. 2017;377:431-41. doi:10.1056/NEJMoa1707278.
16. Revishvili ASh, Shlyakhto EV, Zamyatin MN, et al. Features of emergency and emergency medical care for patients receiving direct oral anticoagulants. Conciliation document of an interdisciplinary expert group. Bulletin of Arrhythmology. 2018;92:59-72. (In Russ.) doi:10.25760/VA-2018-92-59-72.
17. ANDEXXA US prescribing information; https://www.portola.com/wp-content/uploads/Andexxa-prescribing-information-pdf.pdf (4 October 2019)
18. ONDEXXIA SmpC; EMA; https://www.ema.europa.eu/en/documents/product-information/ondexxya-epar-product-information_en.pdf (4 October 2019)
19. www.clinicaltrials.gov (4 October 2019)
20. State register of medicines. (In Russ.) Государственный реестр лекарственных средств; www.grls.rosminzdrav.ru (4 October 2019)
21. WHO global report on falls prevention in older age. World Health Organization 2007. P.48 http://www.who.int/ageing/publications/Falls_prevention7March.pdf (10 September 2019).
22. Melnichenko GA, Belaya ZhE, Rozhinskaya LYa. Federal clinical guidelines for the diagnosis, treatment, and prevention of osteoporosis. Problems of Endocrinology. 2017;63(6):392-426. (In Russ.) doi:10.14341/probl2017636392-426.
23. Miller C. Survival and ambulation following hip fracture. J Bone Joint Surg. 1978;60(7):930-34. ISSN Print: 0021-9355.
24. Dorofeenkov ME, Lee ED, Kuznetsov OO, Konev YuV. Risk factors, clinical features and the prevalence of cholelithiasis in the elderly and senile in Moscow. Clinical Gerontology. 2013;3-4:30-5. (In Russ.)
25. Fries D, Giurea A, Gutl M, et al. Management of dabigatran-induced bleeding expert statement. Wien Klin Wochenschr 2013;125:721-9. doi:10.1007/s00508-013-0430-3.
26. Calkins H, Nordaby M, Gerstenfeld EP, et al. Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation. N Engl J Med. 2017;376(17):1627-36. doi:10.1056/NEJMoa1701005.
27. Cappato R, Marchlinski FE, Hohnloser SH, et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J. 2015;36(28):1805-11. doi:10.1093/eurheartj/ehy176.
28. Kirchhof P, Haeusler KG, Blank B, et al. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. Eur Heart J. 2018;39(32):2942-55. doi:10.1093/eurheartj/ehy176.
29. Instructions for medical use of the drug Xarelto: LP-001457. (In Russ.)
30. Instructions for medical use of the drug Eliquis: LP-002007, L P-001475. (In Russ.)
31. Calkins H, Hindricks G, Cappato R, et al. HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace, 2018;20(1):e1-e160. doi:10.1093/europace/eux274.
32. Revishvili ASh, Antonchenko IV, Ardashev AV, et al. Arrhythmology: Clinical recommendations for electrophysiological studies, catheter ablation and the use of implantable antiarrhythmic devices. M.: GEOTAR Media. 2010. 304 p. (In Russ)
33. Kozluk E, Rodkiewicz D, Piatkowska A, et al. Safety of pulmonary vein isolation in atrial fibrillation patients treated with dabigatran when idarucizumab is available (RCDD code: VIII). J Rare Cardiovasc Dis. 2018;(398):281-3. doi:10.20418/jrcd.v3i8.337.g250.
34. Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012;125(5):669-76. doi:10.1161/CIRCULATIONAHA.111.055970.
35. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91. doi:10.1056/NEJMoa1009638.
36. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. doi:10.1056/NEJMoa1107039.
37. Zelniker TA, Ruff CT, Antman EM, Giugliano RP. The efficacy and safety of non-vitamin K antagonists in patients with atrial fibrillation and coronary artery disease: A meta-analysis of randomized trials. Eur Heart J Acute Cardiovasc Care. 2018 Oct 15:2048872618796990. doi:10.1177/2048872618796990.
38. Fanaroff A. Hasselblad V, Roe MT, et al. Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis. Intern J Cardiol. 2017;241:87-96. doi:10.1016/j.ijcard.2017.03.046.
39. Cannon CP, Gropper S, Bhatt DL, et al. Design and Rationale of the RE-DUAL PCI Trial: A prospective, randomized, phase 3b study comparing the safety and efficacy of dual antithrombotic therapy with dabigatran etexilate versus warfarin triple therapy in patients with nonvalvular atrial fibrillation who have undergone percutaneous coronary intervention with stenting. Clin Cardiol. 2016;39(10):555-64. doi:10.1002/clc.22572.
40. Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513-24. doi:10.1056/NEJMoa1708454.
41. Lopes RD, Heizer G, Aronson R, et al. AUGUSTUS Investigators. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380:1509-24. doi:10.1056/NEJMoa1817083.
42. Chhatriwalla AK, Amin AP, Kennedy KF, et al. Association between bleeding events and inhospital mortality after percutaneous coronary intervention. JAMA. 2013;309(10):1022-9. doi:10.1001/jama.2013.1556.
43. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363-72. doi:10.1161/CIRCULATIONAHA.110.004747.
44. Healey JS, Eikelboom JW, Wallentin L, et al. Effect of age and renal function on the risks of stroke and major bleeding with dabigatran compared to warfarin: an analysis from the RE-LY study. ACC.10, 59th Ann Sci Sess and i2 Summit ‘Innovation in Intervention’ of the American College of Cardiology. Mar 2010, Poster, Abstract: JACC 2010;55(10A);A4.E37. doi:10.1016/S0735-1097(10)60038-1.
45. Danilova IA. Mortality of the elderly from external causes in Russia. Demographic Review. 2014;1(2):56-84. (In Russ.) Данилова И. А. Смертность пожилых от внешних причин в России. Демографическое обозрение. 2014;1(2):56-84. doi:10.17323/demreview.v1i2.1817.
46. Hospital outpatient activity, 2017-18 in English NHS hospitals. National statistics. https://digital.nhs.uk/data-and-information/publications/statistical/hospital-admitted-patient-care-activity/2017-18 (10 September 2019).
Review
For citations:
Baranova E.I., Kobalava Zh. Dabigatran etexilate in patients with nonvalvular atrial fibrillation: benefits of application in certain clinical situations. Russian Journal of Cardiology. 2019;(11):133-141. (In Russ.) https://doi.org/10.15829/1560-4071-2019-11-133-141
Views:
1145
Email this article 